Wall Street Zen upgraded shares of Insulet (NASDAQ:PODD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
Several other analysts have also commented on PODD. Evercore set a $180.00 price target on shares of Insulet in a research report on Monday, July 6th. Benchmark reduced their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company cut shares of Insulet from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $255.00 to $144.00 in a report on Wednesday, August 5th. Citigroup raised their price objective on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $193.48.
Read Our Latest Report on PODD
Insulet Price Performance
Insulet (NASDAQ:PODD – Get Free Report) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same quarter in the prior year, the firm earned $1.17 earnings per share. The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts predict that Insulet will post 6.51 EPS for the current fiscal year.
Institutional Investors Weigh In On Insulet
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC purchased a new position in shares of Insulet in the second quarter worth approximately $6,741,000. OP Asset Management Ltd purchased a new stake in shares of Insulet in the 1st quarter valued at approximately $1,513,000. Amundi boosted its stake in Insulet by 13.6% in the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after purchasing an additional 60,929 shares during the period. SEB Asset Management AB purchased a new position in Insulet during the 1st quarter worth approximately $24,700,000. Finally, Man Group plc purchased a new position in Insulet during the 2nd quarter worth approximately $78,746,000.
Insulet Company Profile
Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.
Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.
See Also
- Five stocks we like better than Insulet
- 3 Unique ETFs With Strong Momentum for the End of the Year
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
